Urinary Tract Infections in Pregnancy Treatment & Management
- Author: Emilie Katherine Johnson, MD; Chief Editor: Edward David Kim, MD, FACS more...
Approach Considerations
Treatment of bacteriuria and cystitis
Because of the dangers of maternal and fetal complications, acute care (eg, in the emergency department [ED]) should focus on identifying and treating asymptomatic and symptomatic bacteriuria, along with ensuring that an alternate process is not the cause of the symptoms.
Treatment of asymptomatic bacteriuria in pregnant patients is important because of the increased risk of urinary tract infection (UTI) and its associated sequelae.[16] ED care may involve the following:
- Administration of appropriate antibiotics
- Administration of fluid if the patient is dehydrated
- Admission if any indication of complicated UTI exists
Behavioral methods
Any discussion of treatment should be prefaced with a discussion of behavioral methods that may be used to ensure good hygiene and reduce bacterial contamination of the urethral meatus, thereby preventing inadequate treatment and recurrent infection. Behavioral methods include the following:
- Avoid baths
- Wipe front-to-back after urinating or defecating
- Wash hands before using the toilet
- Use washcloths to clean the perineum
- Use liquid soap to prevent colonization from bar soap
- Clean the urethral meatus first when bathing
Antibiotic therapy
Oral antibiotics are the treatment of choice for asymptomatic bacteriuria and cystitis. Appropriate oral regimens include the following:
- Cephalexin 500 mg 4 times daily
- Ampicillin 500 mg 4 times daily
- Nitrofurantoin 100 mg twice daily
- Sulfisoxazole 1 g 4 times daily
The resistance of E coli to ampicillin and amoxicillin is 20-40%; accordingly, these agents are no longer considered optimal for treatment of UTIs caused by this organism. Fosfomycin, a phosphonic acid derivative, is useful in the treatment of uncomplicated UTIs caused by susceptible strains of E coli and Enterococcus species. Fosfomycin is a category B agent in pregnancy (ie, fetal risk is not confirmed by human studies but has been shown in some animal studies).
Although 1-, 3-, and 7-day antibiotic courses have been evaluated, 10-14 days of treatment is usually recommended to eradicate the offending bacteria. For example, studies with cephalexin, trimethoprim-sulfamethoxazole, and amoxicillin have indicated that a single dose is as effective as a 3- to 7-day course of therapy, but the cure rate is only 70%. The data are insufficient to justify abandoning the more traditional long-term regimens.
Treatment success depends on eradication of the bacteria rather than on the duration of therapy. A test-for-cure urine culture should show negative findings 1-2 weeks after therapy. A nonnegative culture result is an indication for a 10- to 14-day course of a different antibiotic, followed by suppressive therapy (eg, nitrofurantoin 50 mg at bedtime) until 6 weeks postpartum.
Mathai et al suggest the need for disseminated guidelines for practitioners in developing countries such as India.[17] Their study documented inappropriate use of antibiotics in terms of safety, cost, susceptibility, and threat for developing resistance.
Treatment of pyelonephritis
The standard course of treatment for pyelonephritis consists of hospital admission and intravenous (IV) administration of cephalosporins or gentamicin. IV fluids must be administered with caution. Patients with pyelonephritis can become dehydrated because of nausea and vomiting and need IV hydration. However, they are at high risk for the development of pulmonary edema and acute respiratory distress syndrome (ARDS).
Fever should be managed with antipyretics (preferably, acetaminophen) and nausea and vomiting with antiemetics. Most antiemetics can be used for adverse effects caused by antibiotics, but doxylamine, Emetrol (Wellspring, Sarasota, FL; pregnancy class A), dimenhydrinate, and metoclopramide (pregnancy class B) are preferred.
Preterm labor and delivery are additional risks associated with pyelonephritis. These risks must be evaluated and treated early in the course of admission.
In a randomized, controlled trial of outpatient treatment of pyelonephritis in pregnancy, Millar et al concluded that outpatient therapy is as safe and effective as inpatient care in the treatment of pyelonephritis before 24 weeks’ gestation.[18] However, the prevailing view is still that aggressive inpatient hydration and parenteral antibiotics are necessary. Pyelonephritis places the patient at risk for spontaneous abortion in early pregnancy and for preterm labor after 24 weeks’ gestation.
In their study, Millar et al treated outpatients with 2 doses of intramuscular (IM) ceftriaxone and 10 days of oral cephalexin.[18] Initial outpatient therapy and traditional inpatient therapy failed to cure equal numbers of patients. Benefits include the obvious cost savings and the psychosocial benefits for the patient. Risks include septic shock and respiratory insufficiency at home during outpatient therapy.
Strict guidelines for an observation period before ED discharge, patient education, and home nursing have been discussed. In addition, approximately two thirds of the outpatient treatment group did not complete the study because the subjects developed 1 or more complications.[18] If outpatient therapy is considered, only selected patients in their second trimester should be considered. More study is necessary before a change in the physician’s practice pattern is considered.
Antibiotic selection
Antibiotic selection should be based on urine culture sensitivities, if known. Often, therapy must be initiated on an empirical basis, before culture results are available. This requires clinical knowledge of the most common organisms and their practice-specific or hospital-specific sensitivities to medications.
Institution-specific drug resistances should also be considered before a treatment antibiotic is chosen. For instance, with E coli infection alone, resistance to ampicillin can be as high as 28-39%. Resistance to trimethoprim-sulfamethoxazole has been described as 31%, and resistance to first-generation cephalosporins may be as high as 9-19%.
Maternal physiologic changes that influence pharmacokinetics include increased glomerular filtration rate (GFR) and renal plasma flow, increased volume of distribution, decreased gastric motility and emptying, and decreased albumin levels. Serum levels of antibiotics are lower in pregnancy because of the gross increase in blood volume and the increased GFR.
Some antibiotics should not be used during pregnancy, because of their effects on the fetus. These include tetracyclines (adverse effects on fetal teeth and bones and congenital defects), trimethoprim in the first trimester (facial defects and cardiac abnormalities), chloramphenicol (gray syndrome), and sulfonamides (hemolytic anemia in mothers with glucose-6-phosphate dehydrogenase [G6PD] deficiency, jaundice, and kernicterus) in the third trimester.
Fluoroquinolones are contraindicated in pregnancy. Although in utero exposure is not an indication for termination, fetal exposure to fluoroquinolones has been associated with myelomeningocele, hydrocephaly, hypospadias, maldescended testes, inguinal hernia, bilateral hip dysplasia, and atrial septal defects. That the anomalies seem not to follow a particular pattern may be reassuring; however, a causal relation cannot be excluded.
Nitrofurantoin is safe and effective; however, poor tissue penetration has limited its use in pyelonephritis. In the past, nitrofurantoin was completely avoided in the third trimester because of hemolytic effects on the newborn. Currently, restriction of this agent is limited to the last several weeks of pregnancy. Use during this period can cause hemolytic anemia in the fetus or neonate as a consequence of their immature erythrocyte enzyme systems (glutathione instability). Nitrofurantoin is also safe and effective for once-daily prophylactic therapy during pregnancy.
Macrolides are not first-line agents for UTI in pregnancy. However, they are well tolerated by mother and fetus. A meta-analysis concluded that although antibiotic treatment is effective in patients with UTIs, the data are insufficient to recommend any specific regimen for treatment of symptomatic UTIs during pregnancy.[19, 31] All of the antibiotics studied were effective in terms of both increasing cure rates of UTI in pregnancy and decreasing the incidence of associated adverse outcomes. Current regimens are summarized in Table 1 below.
Table. Treatment Regimens for Pregnant Women with UTI (Open Table in a new window)
| First-line therapy |
|
| Second-line therapy |
|
Surgical treatment
Surgical care is rarely indicated, unless one of the pathologic causes listed in the differential diagnoses is suspected.
In patients with urethral or bladder diverticulum, bladder stones, urethral syndrome, lower urinary tract trauma, interstitial cystitis, or bladder cancer, cystoscopy may aid in establishing the diagnosis.
A retrograde stent or a percutaneous nephrostomy tube should be placed to relieve ureteral colic or decompress an obstructed infected collecting system. More invasive procedures, such as ureteroscopic stone extraction,[30] are rarely indicated. Extracorporeal shock wave lithotripsy (ESWL) is contraindicated in pregnancy.
In the rare patient for whom invasive surgical therapy is indicated, the operation should be planned for the second trimester. Surgical intervention during the first trimester is associated with miscarriage; surgery in the third trimester is associated with preterm labor. Urgent surgical intervention in the third trimester should coincide with delivery of the fetus.
[Guideline] American Academy of Pediatrics and American College of Obstetricians and Gynecology. Guidelines for Perinatal Care. American Academy of Pediatrics. 2007;6th ed.
Smaill F. Asymptomatic bacteriuria in pregnancy. Best Pract Res Clin Obstet Gynaecol. Jun 2007;21(3):439-50. [Medline].
Alvarez JR, Fechner AJ, Williams SF, Ganesh VL, Apuzzio JJ. Asymptomatic bacteriuria in pregestational diabetic pregnancies and the role of group B streptococcus. Am J Perinatol. Mar 2010;27(3):231-4. [Medline].
Hollowell JG. Outcome of pregnancy in women with a history of vesico-ureteric reflux. BJU Int. Sep 2008;102(7):780-4. [Medline].
Ghafari A, Sanadgol H. Pregnancy after renal transplantation: ten-year single-center experience. Transplant Proc. Jan-Feb 2008;40(1):251-2. [Medline].
Versi E, Chia P, Griffiths DJ, Harlow BL. Bacteriuria in pregnancy: a comparison of Bangladeshi and Caucasian women. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(1):8-12. [Medline].
Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome?. J Matern Fetal Neonatal Med. Feb 2009;22(2):124-8. [Medline].
Sheiner E, Mazor-Drey E, Levy A. Asymptomatic bacteriuria during pregnancy. J Matern Fetal Neonatal Med. May 2009;22(5):423-7. [Medline].
Whitehead NS, Callaghan W, Johnson C, Williams L. Racial, ethnic, and economic disparities in the prevalence of pregnancy complications. Matern Child Health J. Mar 2009;13(2):198-205. [Medline].
[Guideline] Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. Mar 1 2005;40(5):643-54. [Medline].
McKenzie H, Donnet ML, Howie PW, Patel NB, Benvie DT. Risk of preterm delivery in pregnant women with group B streptococcal urinary infections or urinary antibodies to group B streptococcal and E. coli antigens. Br J Obstet Gynaecol. Feb 1994;101(2):107-13. [Medline].
Duarte G, Marcolin AC, Quintana SM, Cavalli RC. [Urinary tract infection in pregnancy]. Rev Bras Ginecol Obstet. Feb 2008;30(2):93-100. [Medline].
Vazquez JC, Villar J. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev. 2000;CD002256. [Medline].
Millar LK, Cox SM. Urinary tract infections complicating pregnancy. Infect Dis Clin North Am. Mar 1997;11(1):13-26. [Medline].
Kodikara H, Seneviratne H, Kaluarachchi A, Corea E. Diagnostic accuracy of nitrite dipstick testing for the detection of bacteriuria of pregnancy. Public Health. May 2009;123(5):393-4. [Medline].
Gilstrap LC 3rd, Ramin SM. Urinary tract infections during pregnancy. Obstet Gynecol Clin North Am. Sep 2001;28(3):581-91. [Medline].
Mathai E, Thomas RJ, Chandy S, Mathai M, Bergstrom S. Antimicrobials for the treatment of urinary tract infection in pregnancy: practices in southern India. Pharmacoepidemiol Drug Saf. Sep 2004;13(9):645-52. [Medline].
Millar LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol. Oct 1995;86(4 Pt 1):560-4. [Medline].
Vazquez JC, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev. Jan 19 2011;CD002256. [Medline].
ACOG. ACOG educational bulletin. Antibiotics and gynecologic infections. American College of Obstetricians and Gynecologists. Number 237, June 1997 (Replaces No. 153, March 1991). Int J Gynaecol Obstet. Sep 1997;58(3):333-40. [Medline].
U.S. Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. Jul 1 2008;149(1):43-7. [Medline].
Rouse DJ, Andrews WW, Goldenberg RL, Owen J. Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-effectiveness and cost-benefit analysis. Obstet Gynecol. Jul 1995;86(1):119-23. [Medline].
Thurman AR, Steed LL, Hulsey T, Soper DE. Bacteriuria in pregnant women with sickle cell trait. Am J Obstet Gynecol. May 2006;194(5):1366-70. [Medline].
Wing DA, Rumney PJ, Preslicka CW, Chung JH. Daily cranberry juice for the prevention of asymptomatic bacteriuria in pregnancy: a randomized, controlled pilot study. J Urol. Oct 2008;180(4):1367-72. [Medline]. [Full Text].
Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. Sep 2003;170(3):867-9. [Medline].
Mann JR, McDermott S. Are Maternal Genitourinary Infection and Pre-Eclampsia Associated With ADHD in School Aged Children?. J Atten Disord. Sep 13 2010;[Medline].
Sun Y, Vestergaard M, Christensen J, Nahmias AJ, Olsen J. Prenatal exposure to maternal infections and epilepsy in childhood: a population-based cohort study. Pediatrics. May 2008;121(5):e1100-7. [Medline].
Hill JB, Sheffield JS, McIntire DD, Wendel GD Jr. Acute pyelonephritis in pregnancy. Obstet Gynecol. Jan 2005;105(1):18-23. [Medline].
Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome?. J Matern Fetal Neonatal Med. Feb 2009;22(2):124-8. [Medline].
Bozkurt Y, Penbegul N, Soylemez H, Atar M, Sancaktutar AA, Yildirim K, et al. The efficacy and safety of ureteroscopy for ureteral calculi in pregnancy: our experience in 32 patients. Urol Res. Jan 4 2012;[Medline].
Widmer M, Gülmezoglu AM, Mignini L, Roganti A. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev. Dec 7 2011;12:CD000491. [Medline].
Lichtenberger P, Hooton TM. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents. Dec 2011;38 Suppl:36-41. [Medline].
| First-line therapy |
|
| Second-line therapy |
|

